Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin launches Ipratropium Bromide nasal spray in US
Details : Atrovent-Generic (ipratropium bromide) is an anticholinergic bronchodilator which is indicated for the treatment of rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Product Name : Atrovent-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2025
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval from FDA for Ipratropium Br Nasal Solution
Details : Atrovent-Generic (ipratropium bromide) is an anticholinergic bronchodilator, indicated for treatment of symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Product Name : Atrovent-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2020
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ipratropium Bromide Spray as Treatment for Sialorrhea in Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2018
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2014
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2014
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2014
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2014
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable